Technology transfer is the most critical step in the transition of therapeutic protein and peptide biopharmaceuticals from research and development (R&D) to commercial production (industrialization). Smooth technology transfer is critical to the success and rapid launch of drugs. Successful technology transfer requires careful planning, proper documentation and procedures, and experienced experts to help guide process execution and avoid pitfalls. CD Formulation has a dedicated technology transfer service team that leverages its proven expertise in therapeutic protein and peptide science and manufacturing to seamlessly migrate your production to global locations with minimal disruption to your business.
Technology transfer is the formal process of transferring the production of a drug from one facility, scale, or stage of the drug life cycle to another facility, scale, or stage of the drug life cycle. Bio-process technology transfer for proteins and peptides usually includes the transfer of production processes and analytical methods. Transfers can occur at different stages, and the most common ones are:
As drugs develop from the laboratory to commercial production, pharmaceutical and biotechnology companies often need to transfer technology during the life cycle of drugs for different reasons. For example, 1) Changes in production equipment, methods, and materials lead to process differences, and key process parameters need to be optimized, or the entire process needs to be redeveloped, which may require technology transfer. 2) Some companies need technology transfer because they lack the ability and resources to optimize process optimization, secondary packaging, or optimize product life cycle management. 3) When larger batch production and management requirements are required, companies also need technology transfer to scale up or transfer drugs from one commercial sterile manufacturing facility to another.
Fig. 1 Technology transfer possibilities within a product life cycle, from pre-clinical studies to commercialization. (Chattaway T, 2020)
The core of technology transfer is knowledge transfer. At CD Formulation, our team of technology transfer experts has the expertise to ensure efficient technology transfer of your protein and peptide manufacturing processes and that the final process is aligned with your goals, maximizing the efficiency and success of your technology transfer projects. Our team can provide customized solutions whenever any of the following key factors change.
Our protein and peptide bioprocess transfer model is unmatched in expertise and professionalism. It covers two key phases to ensure your tool transfer is completed efficiently and accurately.
Fig. 2 Types of therapeutic protein/peptide technology transfer. (CD Formulation)
Leveraging our decades of experience and analytical characterization capabilities in protein R&D and production, as well as our successful history of technology and production transfer, our proven processes and dedicated team of experts ensure the seamless execution of large, technically complex projects with minimal disruption.
Our transfer laboratory is well-equipped to efficiently complete technology transfer with customers at any stage of the product development lifecycle. We are able to apply industrial scale-up and scale-down techniques, perform differential analysis for different sites and equipment facilities, and complete technology transfer between different production equipment, production scales, and production platforms.
We have extensive process unit operation expertise for protein and peptide production. Our team of experts develops control strategies to shorten process validation time and reduce costs throughout the product life-cycle.
Published Data
Technology: Safety and Immunogenicity Assessment
Journal: Hum Vaccin Immunother.
IF: 4.1
Published: 2014
Results:
The article describes the development of a new affordable and non-infringing Haemophilus influenzae type b (Hib) conjugate vaccine manufacturing process, including relevant quality control testing, by the Institute for Translational Vaccinology (Intravacc). As part of the Hib technology transfer project managed by intravacc, preclinical toxicity studies were conducted on the novel Hib conjugate vaccine, including testing the safety and immunogenicity of this novel Hib conjugate vaccine. The results showed that the vaccine was well tolerated and immunogenic in rats and that the vaccine produced according to the production process developed by intravacc was not significantly different from the licensed vaccine in terms of both safety and immunogenicity. This enabled the technology transfer partner to implement the original process without changing the manufacturing process and vaccine formulation and to start Phase 1 clinical trials directly.
The execution of bioprocess technology transfer for therapeutic proteins and peptides is critical to ensure smooth knowledge transfer and maximized process reproducibility. As your most loyal partner, CD Formulation is committed to providing the most professional and efficient bioprocess technology transfer services to ensure the smooth production process of your therapeutic proteins and peptides. Please don't hesitate to contact us if you are interested in our services. We look forward to cooperating with you.
References